项目名称: 肿瘤坏死因子预处理及其抗体对体外循环肺保护作用的新机制
项目编号: No.81470529
项目类型: 面上项目
立项/批准年度: 2015
项目学科: 医药、卫生
项目作者: 于洋
作者单位: 首都医科大学
项目金额: 73万元
中文摘要: 肺损伤是体外循环(CPB)术后的常见并发症,从机制进行防治是临床治疗的重点和难点。我们在前期研究中已经明确肿瘤坏死因子(TNF-α)在CPB相关肺损伤中起关键作用,并发现信号通路MAPK相关基因在肺损伤后表达显著升高。因此,我们提出TNF-α保护性预处理及其抗体双重干预MAPK信号通路,减轻CPB相关肺损伤的假说。本项目拟建立兔CPB模型,采用生物信息学、组织形态学、分子生物学、MAPK通道蛋白抑制剂、腺病毒载体转染和RNA干扰等手段,从分子、细胞、组织以及动物水平等层面阐明:1)TNF-α预处理及其抗体对CPB术后肺组织的保护作用;2)TNF-α预处理及其抗体对MAPK信号通路的作用机制;3)明确TNF-α预处理及其抗体作用下的MAPK信号通路的相关靶基因;4)揭示MAPK信号通路与CPB相关肺损伤的关系和TNF-α预处理及其抗体对CPB肺组织的保护机制,为CPB肺保护提供新的思路。
中文关键词: 体外循环;肺损伤;肺保护;肿瘤坏死因子预处理;抗肿瘤坏死因子抗体
英文摘要: Pulmonary injury is a common post-surgery complication associated with cardiopulmonary bypass (CPB). Understanding the mechanism of CPB-induced pulmonary injury is a challenge and the key to effectively manage the complication in clinical practice. Our previous studies have demonstrated that tumor necrosis factor-α (TNF- α) plays a critical role in mediating CPB-induced pulmonary injury. We also found that the expression of genes involved in the mitogen-activated protein kinase (MAPK) signaling pathway is significantly increased in CPB-induced pulmonary injury. In this study, we hypothesize that preventive intervention and neutralizing antibody-targeting TNF-α to interfere MAPK signaling pathway can attenuate CPB-induced pulmonary injury. In this project, we propose to establish a rabbit model of CPB and comprehensively investigate the molecular mechanism and therapeutic intervention of CPB-induced pulmonary injury at molecular, cellular, histological, and animal levels by using approaches in bioinformatics, histomorphology, and molecular biology . The aim of our study is to investigate the protective effects and molecular mechanism of preventive intervention and neutralizing antibody-targeting TNF-α on lung tissue after CPB, and to identify MAPK pathway-associated genes influenced by preventive intervention and neutralizing antibody-targeting TNF-α. Our study will shed new lights on therapeutic targets for pulmonary protection after CPB.
英文关键词: cardiopulmonayr bypass;lung injury;lung protection;pretreatment with tumor necrosis factor;anti-tumor necrosis factor antibody